Induced Pluripotent Stem Cell–Derived Cardiomyocytes: Boutique Science or Valuable Arrhythmia Model?

This article reviews the strengths and limitations of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) as models of cardiac arrhythmias. Specifically, the article attempts to answer the following questions: Which clinical arrhythmias can be modeled by iPSC-CM? How well can iPSC-CM model adult ventricular myocytes? What are the strengths and limitations of published iPSC-CM arrhythmia models? What new mechanistic insight has been gained? What is the evidence that would support using iPSC-CM to personalize antiarrhythmic drug therapy? The review also discusses the pros and cons of using the iPSC-CM technology for modeling specific genetic arrhythmia disorders, such as long QT syndrome, Brugada Syndrome, or Catecholaminergic Polymorphic Ventricular Tachycardia.

[1]  Divya Rajamohan,et al.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European heart journal.

[2]  Jackie Schiller,et al.  Calcium Handling in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes , 2011, PloS one.

[3]  A J Levi,et al.  Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties. , 1998, Cardiovascular research.

[4]  H. Huikuri,et al.  Sudden death due to cardiac arrhythmias. , 2001, The New England journal of medicine.

[5]  A. Zima,et al.  Inositol‐1,4,5‐trisphosphate‐dependent Ca2+ signalling in cat atrial excitation–contraction coupling and arrhythmias , 2004, The Journal of physiology.

[6]  Michael Glikson,et al.  Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. , 2012, Journal of the American College of Cardiology.

[7]  Katriina Aalto-Setälä,et al.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.

[8]  B. Knollmann,et al.  Genetics of sudden cardiac death syndromes , 2011, Current opinion in cardiology.

[9]  James A Thomson,et al.  High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.

[10]  Philip Wong,et al.  Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  田中 智文,et al.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes , 2012 .

[12]  P. Coumel,et al.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.

[13]  Katriina Aalto-Setälä,et al.  Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Reveals Early and Delayed Afterdepolarizations , 2012, PloS one.

[14]  江頭 徹.  Disease characterization using LQTS-specific induced pluripotent stem cells , 2013 .

[15]  Silvia G Priori,et al.  Induced pluripotent stem cell-derived cardiomyocytes and long QT syndrome: is personalized medicine ready for prime time? , 2011, Circulation research.

[16]  D. Roden,et al.  A genetic framework for improving arrhythmia therapy , 2008, Nature.

[17]  Laura Iop,et al.  Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia , 2012, EMBO molecular medicine.

[18]  Philip Wong,et al.  Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.

[19]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[20]  Robert Passier,et al.  Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[21]  Ronald A. Li,et al.  Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. , 2009, Stem cells and development.

[22]  L Gepstein,et al.  Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. , 2001, The Journal of clinical investigation.

[23]  Azra Fatima,et al.  In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.

[24]  D. Kornyeyev,et al.  Role of inositol 1,4,5-trisphosphate in the regulation of ventricular Ca(2+) signaling in intact mouse heart. , 2012, Journal of molecular and cellular cardiology.

[25]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[26]  G. Lyons,et al.  Extracellular Matrix Promotes Highly Efficient Cardiac Differentiation of Human Pluripotent Stem Cells: The Matrix Sandwich Method , 2012, Circulation research.

[27]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[28]  G. Daley,et al.  The promise of induced pluripotent stem cells in research and therapy , 2012, Nature.

[29]  Tao Yang,et al.  Modest Reductions of Cardiac Calsequestrin Increase Sarcoplasmic Reticulum Ca2+ Leak Independent of Luminal Ca2+ and Trigger Ventricular Arrhythmias in Mice , 2007, Circulation research.

[30]  S. Yamanaka,et al.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.

[31]  S. Cala,et al.  Calsequestrin mutant D307H exhibits depressed binding to its protein targets and a depressed response to calcium. , 2004, Cardiovascular research.

[32]  Ronald A. Li,et al.  Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression. , 2009, American journal of physiology. Cell physiology.

[33]  Nan Li,et al.  Functional Cardiotoxicity Profiling and Screening Using the xCELLigence RTCA Cardio System , 2011, Journal of laboratory automation.

[34]  H. Huikuri,et al.  Causes of nonischemic sudden cardiac death in the current era. , 2011, Heart rhythm.

[35]  Euan A. Ashley,et al.  Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.

[36]  D. Malan,et al.  Cardiomyocytes Obtained From Induced Pluripotent Stem Cells With Long-QT Syndrome 3 Recapitulate Typical Disease-Specific Features In Vitro , 2011, Circulation research.

[37]  C. Siu,et al.  Title Calcium Homeostasis in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes , 2011 .

[38]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[39]  J. Itskovitz‐Eldor,et al.  Functional Properties of Human Embryonic Stem Cell–Derived Cardiomyocytes: Intracellular Ca2+ Handling and the Role of Sarcoplasmic Reticulum in the Contraction , 2006, Stem cells.

[40]  Jürgen Hescheler,et al.  In vitro Model for Assessing Arrhythmogenic Properties of Drugs Based on High-resolution Impedance Measurements , 2012, Cellular Physiology and Biochemistry.

[41]  C. Mummery,et al.  Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias , 2012, Front. Physio..

[42]  C. Mummery,et al.  Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease , 2012, Circulation.

[43]  Ofer Binah,et al.  Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.

[44]  M. Faggioni,et al.  Calsequestrin Mutations and Catecholaminergic Polymorphic Ventricular Tachycardia , 2012, Pediatric Cardiology.